Dashboard
Manage Tickers

CLRB Cellectar Biosciences, Inc.

Nasdaq cellectar.com


$ 4.86 $ -0.03 (-0.62 %)    

Tuesday, 14-Oct-2025 12:27:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 601.76 $ 6.53 (1.1 %)
DIA $ 463.90 $ 6.89 (1.51 %)
SPY $ 664.77 $ 7.49 (1.14 %)
TLT $ 90.69 $ 0.06 (0.07 %)
GLD $ 381.81 $ 3.53 (0.93 %)
$ 4.89
$ 4.83
$ 4.82 x 1
$ 4.93 x 200
$ 4.80 - $ 4.88
$ 4.11 - $ 66.00
65,737
na
15.61M
$ 1.67
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-13-2025 12-31-2024 10-K
4 11-18-2024 09-30-2024 10-Q
5 10-29-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-27-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 03-09-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-05-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-21-2022 12-31-2021 10-K
16 11-08-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 03-02-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 03-09-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-12-2019 06-30-2019 10-Q
26 05-06-2019 03-31-2019 10-Q
27 02-26-2019 12-31-2018 10-K
28 11-13-2018 09-30-2018 10-Q
29 08-10-2018 06-30-2018 10-Q
30 05-11-2018 03-31-2018 10-Q
31 03-21-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-14-2017 06-30-2017 10-Q
34 05-11-2017 03-31-2017 10-Q
35 03-15-2017 12-31-2016 10-K
36 11-10-2016 09-30-2016 10-Q
37 08-11-2016 06-30-2016 10-Q
38 05-12-2016 03-31-2016 10-Q
39 03-11-2016 12-31-2015 10-K
40 11-12-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cellectar-biosciences-presented-preclinical-data-on-clr-121225-a-novel-actinium-based-alpha-emitter-for-pancreatic-ductal-adenocarcinoma-which-has-completed-ind-enabling-studies-and-may-advance-to-a-phase-1-trial
Cellectar Biosciences Presented Preclinica...
10/14/2025 12:37:11

Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and develop...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/07/2025 17:06:17

clearsign-receives-initial-cfd-and-engineering-order-from-supermajor-refiner-as-first-phase-of-process-heater-retrofit-for-total-of-32-clearsign-core-burners
ClearSign Receives Initial CFD And Enginee...
10/07/2025 12:36:18

cellectar-biosciences-secures-58m-in-gross-proceeds-through-institutional-warrant-exercise
Cellectar Biosciences Secures $5.8M In Gro...
10/07/2025 12:33:33

cellectar-eyes-2027-eu-launch-as-ema-backs-conditional-approval-path-for-its-blood-cancer-drug
Cellectar Eyes 2027 EU Launch As EMA Backs...
10/06/2025 11:08:17

Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and develop...

cellectar-biosciences-highlights-presentations-at-american-association-for-cancer-research-special-conference-on-discovery-and-innovation-in-pediatric-cancer-sept-25-28
Cellectar Biosciences Highlights Presentat...
09/30/2025 12:38:31

evestia-to-provide-cellectar-with-full-cro-services-for-upcoming-phase-1b-study-evaluating-clr-125-for-treatment-of-triple-negative-breast-cancer
Evestia To Provide Cellectar With Full CRO...
09/24/2025 12:34:44

Cellectar Biosciences, Inc. ("Cellectar") (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the...

cellectar-biosciences-to-present-preclinical-data-on-novel-pancreatic-cancer-therapy-at-aacr-conference
Cellectar Biosciences To Present Preclinic...
09/03/2025 12:08:14

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and develo...

cellectar-to-present-interim-phase-1b-data-on-iopofosine-in-pediatric-brain-cancer-at-aacr-conference
Cellectar To Present Interim Phase 1b Data...
08/27/2025 12:09:38

Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and develop...

cellectar-biosciences-q2-eps-339-beats-398-estimate
Cellectar Biosciences Q2 EPS $(3.39) Beats...
08/14/2025 11:22:46

Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(3.39) per share which beat the analyst consensus estimate of...

Core News & Articles
Earnings Scheduled For August 14, 2025
08/14/2025 08:32:32

a-peek-at-cellectar-biosciencess-future-earnings
A Peek at Cellectar Biosciences's Future E...
08/13/2025 16:03:33

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
07/30/2025 12:08:36

cellectar-biosciences-has-been-granted-european-patent-number-ep3773544-titled-phospholipid-flavagline-conjugates-and-methods-of-using-the-same-for-targeted-cancer-therapy
Cellectar Biosciences Has Been Granted Eur...
07/23/2025 19:58:51

https://data.epo.org/publication-server/publications/pdf?path=2025/30/DOC/EPNWB1/EP19784548NWB1/EP19784548NWB1.pdf

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/01/2025 17:05:56

cellectar-biosciences-prices-6m-offering-of-865k-class-a-units-and-335k-class-b-units-with-warrants-exercisable-at-525-price-per-class-a-unit-is-500-and-the-price-per-class-b-unit-is-499999
Cellectar Biosciences Prices $6M Offering ...
07/01/2025 13:27:11

Cellectar Biosciences, Inc.

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
06/30/2025 21:06:29

cellectar-biosciences-and-nusano-sign-multi-year-supply-agreement-nusano-to-provide-cellectar-with-iodine-125-and-actinium-225-for-clinical-studies-and-future-commercial-needs
Cellectar Biosciences And Nusano Sign Mult...
06/26/2025 12:11:31

Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225Supports Advancement of Radiotherapeutic Pipeline and Plans...

trading-halt-halt-status-updated-at-85500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 8:55:...
06/24/2025 12:55:04

cellectar-biosciences-submits-fda-protocol-for-phase-1b-study-of-clr-125-in-relapsed-triple-negative-breast-cancer
Cellectar Biosciences Submits FDA Protocol...
06/24/2025 12:37:29

Good Tolerability and Robust Tumor Uptake were Observed in TNBC Animal ModelsAuger Emitters Offer the Potential Benefit of Enha...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION